[어바웃G] 온코닉테라퓨틱스 신임 사장에 제일약품 ‘오너3세’ 한상철

The appointment of Han Sang-chul as president signifies a strategic shift to maximize synergy between Onconic Therapeutics' R&D and Jeil Pharmaceutical's commercial infrastructure for the global rollout of Jacuvo. This move is crucial as it tests the viability of the 'profitable biotech' model while serving as a final validation stage for the third-generation leadership succession within the group.